SCHEMBL22200645

SCHEMBL22200645

Nc1ncc2cc(-c3ccc(NSCc4ccccc4F)c(F)c3)c(=O)n(CCO)c2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 2/20 0.38
LYN P07948 1/20 0.38
BTK Q06187 1/20 0.38
BRAF P15056 1/20 0.38
RIPK2 O43353 1/20 0.38
ACVR1 Q04771 1/20 0.38
NOD2 Q9HC29 1/20 0.38
STK4 Q13043 2/20 0.37
STK3 Q13188 2/20 0.37
SIK2 Q9H0K1 2/20 0.37
STK26 Q9P289 2/20 0.37
STK24 Q9Y6E0 2/20 0.37
ALOX5AP P20292 1/20 0.36
FEN1 P39748 1/20 0.36
PIK3CA P42336 1/20 0.35
EGFR P00533 1/20 0.35
FGFR1 P11362 1/20 0.35
FGFR2 P21802 1/20 0.35
FGFR4 P22455 1/20 0.35
FGFR3 P22607 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25035557 0.85 BRAF (0.44) BRAFRIPK2ACVR1NOD2ALOX5AP
SCHEMBL22200559 0.84 ERN1 (0.40) SRCBTKBRAFALOX5APFEN1
SCHEMBL22200758 0.82 BRAF (0.39) SRCBRAFALOX5APFEN1EGFR
SCHEMBL22200440 0.79 ALDH1A1 (0.42) SRCLYNBTKRIPK2ACVR1
SCHEMBL25035385 0.75 BRAF (0.45) SRCBTKBRAFSTK4STK3
SCHEMBL22200566 0.74 ERN1 (0.40) SRCLYNBTKALOX5APFEN1
SCHEMBL22200562 0.74 PIK3CA (0.42) SRCLYNBTKBRAFPIK3CA
SCHEMBL22200391 0.72 ERN1 (0.35) SRCBTKBRAFALOX5APFEN1
SCHEMBL22200366 0.72 ERN1 (0.47) SRCBTKBRAFPIK3CAEGFR
SCHEMBL22200725 0.69 BTK (0.38) SRCBTKBRAFPIK3CAEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed